Citadel Advisors
VTGN icon

Citadel Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Citadel Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.4K Sell
35,700
-429,400
-92% -$261K ﹤0.01% 12666
2025
Q4 		$308K Buy
465,100
+365,600
+367% +$1.32M ﹤0.01% 10088
2025
Q3 		$353K Buy
99,500
+63,600
+177% +$190K ﹤0.01% 9974
2025
Q2 		$71.8K Buy
35,900
+34,700
+2,892% +$78.8K ﹤0.01% 11568
2025
Q1 		$3K Sell
1,200
-53,400
-98% -$151K ﹤0.01% 13995
2024
Q4 		$161K Sell
54,600
-900
-2% -$2.53K ﹤0.01% 10779
2024
Q3 		$167K Buy
55,500
+26,700
+93% +$91.1K ﹤0.01% 10418
2024
Q2 		$100K Buy
28,800
+4,900
+21% +$21.2K ﹤0.01% 10918
2024
Q1 		$126K Sell
23,900
-14,800
-38% -$71.2K ﹤0.01% 11040
2023
Q4 		$199K Sell
38,700
-11,300
-23% -$42.8K ﹤0.01% 9966
2023
Q3 		$262K Buy
+50,000
New +$222K ﹤0.01% 9407
2022
Q4 		– Sell
-1,307
Closed -$6K – 15518
2022
Q3 		$6K Sell
1,307
-2,420
-65% -$24K ﹤0.01% 12351
2022
Q2 		$98K Buy
3,727
+2,714
+268% +$95.8K ﹤0.01% 11431
2022
Q1 		$38K Sell
1,013
-1,317
-57% -$57.4K ﹤0.01% 12971
2021
Q4 		$136K Sell
2,330
-1,457
-38% -$94.8K ﹤0.01% 12389
2021
Q3 		$311K Buy
+3,787
New +$329K ﹤0.01% 11002

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's VTGN Position: Q4 2025 in Review

Citadel Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 122,062 shares — an estimated $441K sold.

Citadel Advisors first reported a position in VTGN in Q3 2017 and held it in 18 quarters. The position peaked at $3.93M in Q1 2024. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Citadel Advisors reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 122,062 VistaGen Therapeutics shares in Q4 2025, an estimated $441K.
  • Citadel Advisors first reported a position in VistaGen Therapeutics in Q3 2017 and held it in 18 quarters.
  • Citadel Advisors's VistaGen Therapeutics position peaked at $3.93M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.